SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lin, Y. Articles by Hebbel, R. P. Search for Related Content PubMed PubMed Citation Articles by Lin, Y. Articles by Hebbel, R. P. Related Collections Hemostasis, Thrombosis, and Vascular Biology Gene Therapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 January 2002, Vol. 99, No. 2, pp. 457-462 GENE THERAPY Use of blood outgrowth endothelial cells for gene therapy for hemophilia A Yi Lin, Liming Chang, Anna Solovey, John F. Healey, Pete Lollar, and Robert P. Hebbel From the Department of Medicine, University of Minnesota Medical School, Minneapolis, and the Winship Cancer Center, Emory University, Atlanta, GA. A culture of human blood outgrowth endothelial cells (BOECs) was established from a sample of peripheral blood and was transfected using a nonviral plasmid carrying complementary DNA for modified human coagulation factor VIII (B domain deleted and replaced with green fluorescence protein). BOECs were then chemically selected, expanded, cryopreserved, and re-expanded in culture. Stably transfected BOECs were administered intravenously daily for 3 days to NOD/SCID mice at 4 cell dose levels (from 5 × 104 to 40 × 104 cells per injection). In 156 days of observation, mice showed levels of human FVIII that increased with cell dose and time. Mice in all cell dose groups achieved therapeutic levels (more than 10 ng/mL) of human FVIII, and mice in the 3 highest dose groups acquired levels that were normal (100-200 ng/mL) or even above the normal range (highest observed value, 1174 ng/mL). These levels indicate that the BOECs expanded in vivo after administration. When the mice were killed, it was found that BOEC accumulated only in bone marrow and spleen and that these cells retained endothelial phenotype and transgene expression. Cell doses used here would make scale-up to humans feasible. Thus, the use of engineered autologous BOECs, which here resulted in sustained and therapeutic levels of FVIII, may comprise an effective therapeutic strategy for use in gene therapy for hemophilia A. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: L. Chang Milbauer, P. Wei, J. Enenstein, A. Jiang, C. A. Hillery, J. P. Scott, S. C. Nelson, V. Bodempudi, J. N. Topper, R.-B. Yang, et al. Genetic endothelial systems biology of sickle stroke risk Blood, April 1, 2008; 111(7): 3872 - 3879. [Abstract] [Full Text] [PDF] H. Matsui, M. Shibata, B. Brown, A. Labelle, C. Hegadorn, C. Andrews, R. P. Hebbel, J. Galipeau, C. Hough, and D. Lillicrap Ex Vivo Gene Therapy for Hemophilia A That Enhances Safe Delivery and Sustained In Vivo Factor VIII Expression from Lentivirally Engineered Endothelial Progenitors Stem Cells, October 1, 2007; 25(10): 2660 - 2669. [Abstract] [Full Text] [PDF] M. Othman, A. Labelle, I. Mazzetti, H. S. Elbatarny, and D. Lillicrap Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance Blood, April 1, 2007; 109(7): 2832 - 2839. [Abstract] [Full Text] [PDF] S. V. Pislaru, A. Harbuzariu, R. Gulati, T. Witt, N. P. Sandhu, R. D. Simari, and G. S. Sandhu Magnetically Targeted Endothelial Cell Localization in Stented Vessels J. Am. Coll. Cardiol., November 7, 2006; 48(9): 1839 - 1845. [Abstract] [Full Text] [PDF] W. Pan, X. Shen, A. Jiang, and R. P. Hebbel Semi-supervised learning via penalized mixture model with application to microarray sample classification Bioinformatics, October 1, 2006; 22(19): 2388 - 2395. [Abstract] [Full Text] [PDF] S. F. De Meyer, K. Vanhoorelbeke, M. K. Chuah, I. Pareyn, V. Gillijns, R. P. Hebbel, D. Collen, H. Deckmyn, and T. VandenDriessche Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor Blood, June 15, 2006; 107(12): 4728 - 4736. [Abstract] [Full Text] [PDF] A. Fernandez-L, F. Sanz-Rodriguez, F. J. Blanco, C. Bernabeu, and L. M. Botella Hereditary Hemorrhagic Telangiectasia, a Vascular Dysplasia Affecting the TGF-{beta} Signaling Pathway. Clin. Med. Res., March 1, 2006; 4(1): 66 - 78. [Abstract] [Full Text] [PDF] E. Rohde, C. Malischnik, D. Thaler, T. Maierhofer, W. Linkesch, G. Lanzer, C. Guelly, and D. Strunk Blood Monocytes Mimic Endothelial Progenitor Cells Stem Cells, February 1, 2006; 24(2): 357 - 367. [Abstract] [Full Text] [PDF] B. C. Isenberg, C. Williams, and R. T. Tranquillo Small-Diameter Artificial Arteries Engineered In Vitro Circ. Res., January 6, 2006; 98(1): 25 - 35. [Abstract] [Full Text] [PDF] S. J. Stachelek, I. Alferiev, J. M. Connolly, M. Sacks, R. P. Hebbel, R. Bianco, and R. J. Levy Cholesterol-Modified Polyurethane Valve Cusps Demonstrate Blood Outgrowth Endothelial Cell Adhesion Post-Seeding In Vitro and In Vivo Ann. Thorac. Surg., January 1, 2006; 81(1): 47 - 55. [Abstract] [Full Text] [PDF] J. W. Liu, G. Pernod, S. Dunoyer-Geindre, R. J. Fish, H. Yang, H. Bounameaux, and E. K. O. Kruithof Promoter Dependence of Transgene Expression by Lentivirus-Transduced Human Blood-Derived Endothelial Progenitor Cells Stem Cells, January 1, 2006; 24(1): 199 - 208. [Abstract] [Full Text] [PDF] R. P. Hebbel, L. Milbauer, M. Roney, D. Lillicrap, J. Voorberg, and T. C. Nichols Use of Engineered Autologous BOEC for Gene Therapy of Canine Hemophilia A. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 1281 - 1281. [Abstract] A. Fernandez-L, F. Sanz-Rodriguez, R. Zarrabeitia, A. Perez-Molino, R. P. Hebbel, J. Nguyen, C. Bernabeu, and L.-M. Botella Blood outgrowth endothelial cells from Hereditary Haemorrhagic Telangiectasia patients reveal abnormalities compatible with vascular lesions Cardiovasc Res, November 1, 2005; 68(2): 235 - 248. [Abstract] [Full Text] [PDF] L. Xu, T. C. Nichols, R. Sarkar, S. McCorquodale, D. A. Bellinger, and K. P. Ponder Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy PNAS, April 26, 2005; 102(17): 6080 - 6085. [Abstract] [Full Text] [PDF] J. R. Ohlfest, J. L. Frandsen, S. Fritz, P. D. Lobitz, S. G. Perkinson, K. J. Clark, G. Nelsestuen, N. S. Key, R. S. McIvor, P. B. Hackett, et al. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system Blood, April 1, 2005; 105(7): 2691 - 2698. [Abstract] [Full Text] [PDF] J. D. Pearson Using Endothelial Progenitor Cells for Gene Therapy Arterioscler. Thromb. Vasc. Biol., December 1, 2003; 23(12): 2117 - 2118. [Full Text] [PDF] C. Herder, T. Tonn, R. Oostendorp, S. Becker, U. Keller, C. Peschel, M. Grez, and E. Seifried Sustained Expansion and Transgene Expression of Coagulation Factor VIII-Transduced Cord Blood-Derived Endothelial Progenitor Cells Arterioscler. Thromb. Vasc. Biol., December 1, 2003; 23(12): 2266 - 2272. [Abstract] [Full Text] [PDF] H. V. Yarovoi, D. Kufrin, D. E. Eslin, M. A. Thornton, S. L. Haberichter, Q. Shi, H. Zhu, R. Camire, S. S. Fakharzadeh, M. A. Kowalska, et al. Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment Blood, December 1, 2003; 102(12): 4006 - 4013. [Abstract] [Full Text] [PDF] M. E. Rick, C. E. Walsh, and N. S. Key Congenital Bleeding Disorders Hematology, January 1, 2003; 2003(1): 559 - 574. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020